- Home
- GMAB vs LII Comparison
GMAB vs LII Comparison
Compare GMAB & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- LII
- Stock Information
- Founded
- GMAB 1999
- LII 1895
- Country
- GMAB Denmark
- LII United States
- Employees
- GMAB N/A
- LII N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- LII Industrial Machinery/Components
- Sector
- GMAB Health Care
- LII Industrials
- Exchange
- GMAB Nasdaq
- LII Nasdaq
- Market Cap
- GMAB 17.4B
- LII 20.3B
- IPO Year
- GMAB N/A
- LII 1999
- Fundamental
- Price
- GMAB $32.12
- LII $550.41
- Analyst Decision
- GMAB Strong Buy
- LII Hold
- Analyst Count
- GMAB 7
- LII 12
- Target Price
- GMAB $41.17
- LII $627.73
- AVG Volume (30 Days)
- GMAB 2.2M
- LII 436.0K
- Earning Date
- GMAB 11-05-2025
- LII 10-22-2025
- Dividend Yield
- GMAB N/A
- LII 0.94%
- EPS Growth
- GMAB 77.72
- LII 29.66
- EPS
- GMAB 21.62
- LII 23.38
- Revenue
- GMAB $3,646,881,232.00
- LII $5,416,600,000.00
- Revenue This Year
- GMAB $24.25
- LII $2.62
- Revenue Next Year
- GMAB $16.29
- LII $6.39
- P/E Ratio
- GMAB $1.51
- LII $23.72
- Revenue Growth
- GMAB 32.97
- LII 7.91
- 52 Week Low
- GMAB $17.24
- LII $500.10
- 52 Week High
- GMAB $33.63
- LII $689.44
- Technical
- Relative Strength Index (RSI)
- GMAB 72.36
- LII 50.55
- Support Level
- GMAB $28.36
- LII $534.96
- Resistance Level
- GMAB $33.63
- LII $558.26
- Average True Range (ATR)
- GMAB 0.62
- LII 12.48
- MACD
- GMAB 0.11
- LII 4.54
- Stochastic Oscillator
- GMAB 72.68
- LII 83.26
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.